Smith Chas P & Associates PA Cpas Increases Stock Position in Novo Nordisk A/S $NVO

Smith Chas P & Associates PA Cpas boosted its position in shares of Novo Nordisk A/S (NYSE:NVO) by 18.5% during the 2nd quarter, Holdings Channel reports. The institutional investor owned 950,151 shares of the company’s stock after acquiring an additional 148,565 shares during the period. Novo Nordisk A/S makes up approximately 2.2% of Smith Chas P & Associates PA Cpas’ portfolio, making the stock its 18th largest position. Smith Chas P & Associates PA Cpas’ holdings in Novo Nordisk A/S were worth $45,550,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Keystone Financial Planning Inc. acquired a new stake in shares of Novo Nordisk A/S during the 2nd quarter valued at about $336,000. The Manufacturers Life Insurance Company raised its holdings in Novo Nordisk A/S by 22.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 229,607 shares of the company’s stock worth $11,007,000 after purchasing an additional 42,361 shares during the period. Sequoia Financial Advisors LLC raised its holdings in Novo Nordisk A/S by 28.8% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 46,177 shares of the company’s stock worth $2,214,000 after purchasing an additional 10,339 shares during the period. Arlington Capital Management Inc. purchased a new position in Novo Nordisk A/S during the second quarter worth approximately $260,000. Finally, Archford Capital Strategies LLC purchased a new position in Novo Nordisk A/S during the second quarter worth approximately $257,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Wegovy received approval in China for MASH, making it the first GLP-1 receptor agonist in the country approved for the liver disease. The decision expands semaglutide’s potential beyond obesity and diabetes, although Novo has not provided a launch schedule or revenue outlook. Reuters article
• Positive Sentiment: China’s acceptance of Novo’s oral Wegovy application creates a potential avenue into the country’s growing GLP-1 weight-management market. Investors see the opportunity as a possible long-term growth driver, though regulatory approval, launch timing and competitive dynamics remain uncertain. Oral Wegovy China article
• Neutral Sentiment: HSBC raised its price target to 320 Danish kroner but kept a Hold rating, reflecting improved valuation expectations without a strong near-term conviction. HSBC price target article
• Positive Sentiment: Some analysts continue to view Novo’s valuation, strong margins, free cash flow and GLP-1 leadership as providing a margin of safety, suggesting the recent weakness may already reflect substantial execution and competitive risks. Novo Nordisk valuation analysis
• Negative Sentiment: The Morgan Stanley downgrade is the dominant near-term catalyst. Investors are questioning whether oral Wegovy, China expansion and other pipeline opportunities can replace revenue exposed to the semaglutide patent cliff, contributing to NVO’s decline and keeping sentiment weak. Morgan Stanley downgrade article

Analyst Ratings Changes

A number of analysts have recently commented on NVO shares. HSBC restated a “hold” rating on shares of Novo Nordisk A/S in a research report on Thursday. BMO Capital Markets reiterated a “market perform” rating and set a $47.00 target price on shares of Novo Nordisk A/S in a research report on Thursday, August 6th. Berenberg Bank set a $47.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday, August 12th. Nordea Equity Research raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Friday, June 19th. Finally, Weiss Ratings upgraded shares of Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, August 5th. Four investment analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $64.94.

Novo Nordisk A/S Price Performance

Shares of Novo Nordisk A/S stock traded down $0.98 during trading hours on Friday, reaching $43.03. 11,004,048 shares of the company’s stock were exchanged, compared to its average volume of 17,175,861. The business has a fifty day moving average of $47.63 and a two-hundred day moving average of $43.65. The company has a market capitalization of $192.15 billion, a P/E ratio of 10.52, a price-to-earnings-growth ratio of 1.50 and a beta of 0.74. The company has a quick ratio of 0.56, a current ratio of 0.79 and a debt-to-equity ratio of 0.59. Novo Nordisk A/S has a 1 year low of $35.12 and a 1 year high of $64.16.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Tuesday, June 30th. The company reported $0.94 earnings per share for the quarter. Novo Nordisk A/S had a net margin of 35.36% and a return on equity of 61.20%. The business had revenue of $11.98 billion for the quarter. As a group, research analysts predict that Novo Nordisk A/S will post 3.45 earnings per share for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The firm also recently declared a dividend, which was paid on Tuesday, August 25th. Stockholders of record on Monday, August 17th were paid a $0.5786 dividend. This represents a dividend yield of 258.0%. The ex-dividend date of this dividend was Monday, August 17th. Novo Nordisk A/S’s dividend payout ratio is 20.05%.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish healthcare company headquartered in Bagsværd, Denmark. Founded in 1923, the company develops and manufactures pharmaceutical products focused primarily on diabetes and obesity care, as well as treatments for rare blood disorders and growth disorders.

Its diabetes portfolio includes insulin products and medicines in the glucagon-like peptide-1 (GLP-1) class, including Ozempic, Rybelsus and Wegovy. The company also offers treatments for obesity, hemophilia and other rare conditions, along with growth hormone therapies.